✦ LIBER ✦

eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease

✍ Scribed by N. Pedersen; M. Elkjaer; D. Duricova; J. Burisch; C. Dobrzanski; N. N. Andersen; T. Jess; F. Bendtsen; E. Langholz; S. Leotta; T. Knudsen; N. Thorsgaard; P. Munkholm

Book ID: 117940045
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 326 KB
Volume: 36
Category: Article
ISSN: 0269-2813
DOI: 10.1111/apt.12043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P293 eHealth: Individualisation of MMX m

P293 eHealth: Individualisation of MMX mesalamine treatment and optimization of disease course via a self-managed web-based solution in active ulcerative colitis

✍ Pedersen, N.; Burisch, J.; Martinsen, L.; Bennedsen, M.; Thielsen, P.; Bell, S.; 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 49 KB

Ehealth: Impact of Web-Based Treatment O

Ehealth: Impact of Web-Based Treatment Optimization Solution (Traffic Light) on the Quality of Life in Crohn's Disease Patients Treated With Infliximab

✍ Dana Duricova; Natalia Pedersen; Johan Burisch; Margarita Elkjaer; Christian Dob 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 274 KB

94 Treatment of Secondary Infliximab Fai

94 Treatment of Secondary Infliximab Failure in Crohn's Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab: The Danish Study of Optimizing Infliximab Therapy in Crohn's Disease (Do It Crohn) Randomized Clinical Trial

✍ Steenholdt, Casper; Brynskov, Jorn; Thomsen, Ole.; Munck, Lars K.; Fallingborg, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Long-term outcome of treatment with infl

Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study

✍ Valérie Crombé; Julia Salleron; Guillaume Savoye; Jean-Louis Dupas; Gwénola Vern 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

Background: We examined short-and long-term benefits and safety of infliximab (IFX) in a population-based cohort of Crohn's disease (CD) patients <17 years old at diagnosis. ## Methods: The following parameters were assessed: short-and long-term efficacy of IFX, impact of drug efficacy, and mode

P120 IMPACT OF THE AVAILABILITY OF IMMUN

P120 IMPACT OF THE AVAILABILITY OF IMMUNEMODULATORS OR INFLIXIMAB ON THE TREATMENT AND DISEASE COURSE IN TWO HOSPITAL COHORTS OF NEWLY-DIAGNOSED CROHN'S DISEASE (CD) PATIENTS

✍ E. Domènech; Y. Zabana; E. Garcia-Planella; A. López-San Román; P. Nos; D. Ginar 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 66 KB

P254 Effect of standard treatment (ST) v

P254 Effect of standard treatment (ST) versus episodic (ET) or maintenance (MT) infliximab on healthcare cost (HC) and quality-adjusted life years (QALYs) in a community-based incidence cohort of adult Crohn's disease patients with 10 years follow-up

✍ S. Odes; H. Vardi; D. Greenberg; M. Friger; R. Stockbrugger; B. Moum; C. O'Morai 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 120 KB